Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Highly Accessed Open Badges Review

Molecular action of methotrexate in inflammatory diseases

Edwin SL Chan and Bruce N Cronstein*

Author Affiliations

Division of Clinical Pharmacology, NYU School of Medicine, New York, NY, USA

For all author emails, please log on.

Arthritis Res 2002, 4:266-273  doi:10.1186/ar419

Published: 19 March 2002


Despite the recent introduction of biological response modifiers and potent new small-molecule antirheumatic drugs, the efficacy of methotrexate is nearly unsurpassed in the treatment of inflammatory arthritis. Although methotrexate was first introduced as an antiproliferative agent that inhibits the synthesis of purines and pyrimidines for the therapy of malignancies, it is now clear that many of the anti-inflammatory effects of methotrexate are mediated by adenosine. This nucleoside, acting at one or more of its receptors, is a potent endogenous anti-inflammatory mediator. In confirmation of this mechanism of action, recent studies in both animals and patients suggest that adenosine-receptor antagonists, among which is caffeine, reverse or prevent the anti-inflammatory effects of methotrexate.

adenosine receptor; inflammation; methotrexate; rheumatoid arthritis